Blood:抗凝药物不能阻断组织因子和血小板触发的静脉血栓形成

2019-03-23 不详 MedSci原创

中心点:抗凝血酶和C蛋白被抑制后,组织因子和血小板是小鼠静脉血栓形成的限速因子。在本动物模型中,凝血因子XII和循环中的中性粒细胞不限制静脉血栓形成的速度。摘要:组织因子、凝血因子XII、血小板和中性粒细胞在静脉血栓形成(VT)的病理生理过程中具有重要作用。在需要手术处理才能诱发VT的小鼠模型中,它们的作用变得很明显。在小鼠中,仅采用小干扰RNA(siRNA)联合抑制天然抗凝血剂抗凝血酶(Serp

中心点:

抗凝血酶和C蛋白被抑制后,组织因子和血小板是小鼠静脉血栓形成的限速因子。

在本动物模型中,凝血因子XII和循环中的中性粒细胞不限制静脉血栓形成的速度。

摘要:

组织因子、凝血因子XII、血小板和中性粒细胞在静脉血栓形成(VT)的病理生理过程中具有重要作用。在需要手术处理才能诱发VT的小鼠模型中,它们的作用变得很明显。在小鼠中,仅采用小干扰RNA(siRNA)联合抑制天然抗凝血剂抗凝血酶(Serpinc1)和蛋白C (Proc)也可导致静脉血栓形成表型,最明显的是头部大静脉血管阻塞。VT可致死,但通过抑制凝血酶可完全挽救。

在本研究中,研究人员采用VT小鼠模型来研究组织因子、凝血因子XII、血小板和中性粒细胞在静脉血栓形成过程中的作用。

抗体介导的组织因子抑制可降低VT、头部凝血和肝内纤维蛋白沉积的临床特征。相反,凝血因子XII的遗传缺陷和siRNA介导敲除凝血因子XII均不影响VT的发生、严重程度和血栓形态。抗体介导耗竭血小板可完全消除头部凝血和肝纤维蛋白沉积。虽然血栓性病灶中有大量的中性粒细胞,但耗竭循环中Ly6G阳性的中性粒细胞不会改变VT的发生、严重程度、血栓形态以及肝纤维蛋白沉积。

总而言之,凝血酶和蛋白C被抑制后,静脉血栓形成依赖于组织因子和血小板,而不依赖于凝血因子XII和循环中性粒细胞。本研究表明在小鼠静脉血栓形成的过程中,不同的促凝通路在发挥作用,依赖于触发刺激。



原始出处:

Marco Heestermans, et al.Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils.Blood 2019 :blood-2018-06-853762; doi: https://doi.org/10.1182/blood-2018-06-853762

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955426, encodeId=109119554268e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 05 14:46:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710180, encodeId=c1181e10180cc, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri May 24 14:46:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697872, encodeId=2e45169e87242, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 10:46:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664389, encodeId=176a166438939, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Fri Oct 18 02:46:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483282, encodeId=3c4f1483282e4, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Mar 25 10:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-11-05 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955426, encodeId=109119554268e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 05 14:46:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710180, encodeId=c1181e10180cc, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri May 24 14:46:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697872, encodeId=2e45169e87242, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 10:46:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664389, encodeId=176a166438939, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Fri Oct 18 02:46:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483282, encodeId=3c4f1483282e4, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Mar 25 10:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955426, encodeId=109119554268e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 05 14:46:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710180, encodeId=c1181e10180cc, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri May 24 14:46:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697872, encodeId=2e45169e87242, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 10:46:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664389, encodeId=176a166438939, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Fri Oct 18 02:46:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483282, encodeId=3c4f1483282e4, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Mar 25 10:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-07-29 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955426, encodeId=109119554268e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 05 14:46:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710180, encodeId=c1181e10180cc, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri May 24 14:46:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697872, encodeId=2e45169e87242, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 10:46:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664389, encodeId=176a166438939, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Fri Oct 18 02:46:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483282, encodeId=3c4f1483282e4, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Mar 25 10:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955426, encodeId=109119554268e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Nov 05 14:46:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710180, encodeId=c1181e10180cc, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri May 24 14:46:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697872, encodeId=2e45169e87242, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 10:46:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664389, encodeId=176a166438939, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Fri Oct 18 02:46:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483282, encodeId=3c4f1483282e4, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Mar 25 10:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]

相关资讯

J Thromb Haemost:他汀类药物可以降低复发性静脉血栓形成风险

根据一项以人群为基础的队列研究的结果,对于既往发生过静脉血栓形成的患者,使用他汀类药物可以降低复发性静脉血栓形成的风险。 华盛顿大学流行病学系教授Nicholas L. Smith博士称:虽然抗凝治疗可有效的预防血栓复发,但长期治疗存在大出血风险。如果能寻找到既不增加出血风险,又可以降低复发风险的替代方法就是提高临床管理的关键。 因此他们进行了研究,评估他汀类药物能否降低复发性静脉血栓

J Thromb Haemost:超重和肥胖与复发性静脉血栓形成有关吗?

研究人员发现超重与复发性静脉血栓形成之间并不存在相关性。测量BMI并不是一个有用的工具,以确定复发性静脉血栓形成高风险的患者。

Circulation:研究发现肾功能受损对静脉血栓形成的影响机制

荷兰一项研究表明,肾功能受损对静脉血栓形成的影响通过VIII因子和血管性血友病因子(VWF)水平同时升高来实现。论文11月8日在线发表于《循环》(Circulation)。 此项研究共纳入2473例静脉血栓形成患者和2936例对照者,并计算了受试者的估计肾小球滤过率(eGFR)。基于对照组eGFR百分位数将肾功能分为6项分类(>50百分位数[参照]、10~50百分位数、5~10百分

Eur Heart J:服用瑞舒伐他汀改善静脉血栓形成患者凝血功能!

由此可见,20mg/天的瑞舒伐他汀治疗可以显著改善了既往VT患者的凝血功能。这些结果表明他汀治疗可能有益于有复发性VT风险的患者。

SCI REP:癌症患者组织因子结合MPs与静脉血栓形成风险之间的相关性分析!

总之,TF-MPs与癌症患者静脉血栓栓塞的风险增加有关。然而,需要更精心设计的研究以及对混杂因素进行更全面的调整来证实这种相关性。

NEJM:XI因子抑制剂预防静脉血栓形成安全有效

近日,一项II期试验发现,一个新型的抗凝药物—XI因子抑制剂可有效降低全膝关节置换术后静脉血栓栓塞症的风险,并且不会增加出血风险。[pdf free] 全膝关节置换术后患者的静脉血栓栓塞症的风险升高,而传统的预防治疗方法包括使用Xa因子抑制剂或凝血酶抑制剂,尽管这类药物很有效,但患者的出血风险也相应升高。 外科手术后出现静脉血栓栓塞症的发病机制仍不明确,但组织因子暴露于手术部位激活